Pharmaceuticals company Divi's Laboratories announced consolidated FY23 results: Total income of Rs 8,112 crore for FY23 as against Rs 9,074 crore during FY22 Total income is about 11 % lower than FY22 because of a significantly lower volume of covid situational opportunity PBT for FY23 came to Rs 2,369 crore as against Rs 3,684 crore for FY22 PAT for FY23 amounted to Rs 1,823 crore as against a PAT of Rs 2,960 crore The board of directors of the company has proposed a dividend of Rs 30 per share of face value Rs 2 each i.e., 1500% for FY23, subject to approval of members. Result PDF